• Je něco špatně v tomto záznamu ?

The interaction between NK cells and ILC cells and their subsets in atopic dermatitis patients with and without dupilumab therapy

P. Boudkova, E. Čermáková, J. Krejsek, J. Čelakovská

. 2024 ; 136 (-) : 112327. [pub] 20240530

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013318

BACKGROUND: Natural killer cells (NK) and innate lymphoid cells with their subsets (ILC) are part of the innate immune system. OBJECTIVE: The aim is to evaluate how NK cells and ILC cells interact in atopic dermatitis (AD) patients (with and without dupilumab therapy) compared to control group. MATERIALS AND METHODS: Complete dermatological examination was performed in all patients included in the study (19 AD patients with dupilumab, 17 AD patients without dupilumab). Surface molecules expressed on NK cells and ILC cells were analyzed by flow cytometry. The association between NK cells and total ILC cells, ILC-1, ILC-2, ILC-3, NCR+ILC3, NCR-ILC3 were compared in AD patients and in the control group. The non-parametric Spearman's rank correlation coefficient was used for this statistical analysis. We evaluated the association of parameters with AD severity at the time of treatment.Non-parametric Mann-Whitney, Kolmogorov-Smirnov tests were used. RESULTS: We confirmed the higher association between NK cells and total ILC cells in AD patients without dupilumab therapy (in 30.3 %) and in healthy controls (in 27.2 %); this association is low in AD patients with dupilumab therapy (in 0.1 %). The higher association was confirmed between NK cells and ILCs subsets only in AD patients without dupilumab therapy; in these patients the highest association was confirmed between NK cells and ILC-2 cells (in 38.6 %). No statistically significant difference in the count of NK cells and ILC cells was found between mild and moderate form of AD patients treated with dupilumab. CONCLUSION: Targeting these cell types or the cytokines they produce could represent potential therapeutic strategies for controlling inflammation and alleviating symptoms in AD patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013318
003      
CZ-PrNML
005      
20240905133828.0
007      
ta
008      
240725e20240530ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.intimp.2024.112327 $2 doi
035    __
$a (PubMed)38820963
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Boudkova, Petra $u Department of Clinical Immunology and Allergy, Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, 50002, Czech Republic
245    14
$a The interaction between NK cells and ILC cells and their subsets in atopic dermatitis patients with and without dupilumab therapy / $c P. Boudkova, E. Čermáková, J. Krejsek, J. Čelakovská
520    9_
$a BACKGROUND: Natural killer cells (NK) and innate lymphoid cells with their subsets (ILC) are part of the innate immune system. OBJECTIVE: The aim is to evaluate how NK cells and ILC cells interact in atopic dermatitis (AD) patients (with and without dupilumab therapy) compared to control group. MATERIALS AND METHODS: Complete dermatological examination was performed in all patients included in the study (19 AD patients with dupilumab, 17 AD patients without dupilumab). Surface molecules expressed on NK cells and ILC cells were analyzed by flow cytometry. The association between NK cells and total ILC cells, ILC-1, ILC-2, ILC-3, NCR+ILC3, NCR-ILC3 were compared in AD patients and in the control group. The non-parametric Spearman's rank correlation coefficient was used for this statistical analysis. We evaluated the association of parameters with AD severity at the time of treatment.Non-parametric Mann-Whitney, Kolmogorov-Smirnov tests were used. RESULTS: We confirmed the higher association between NK cells and total ILC cells in AD patients without dupilumab therapy (in 30.3 %) and in healthy controls (in 27.2 %); this association is low in AD patients with dupilumab therapy (in 0.1 %). The higher association was confirmed between NK cells and ILCs subsets only in AD patients without dupilumab therapy; in these patients the highest association was confirmed between NK cells and ILC-2 cells (in 38.6 %). No statistically significant difference in the count of NK cells and ILC cells was found between mild and moderate form of AD patients treated with dupilumab. CONCLUSION: Targeting these cell types or the cytokines they produce could represent potential therapeutic strategies for controlling inflammation and alleviating symptoms in AD patients.
650    _2
$a lidé $7 D006801
650    12
$a atopická dermatitida $x farmakoterapie $x imunologie $7 D003876
650    12
$a humanizované monoklonální protilátky $x terapeutické užití $x farmakologie $7 D061067
650    12
$a buňky NK $x imunologie $x účinky léků $7 D007694
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dospělí $7 D000328
650    _2
$a lidé středního věku $7 D008875
650    _2
$a přirozená imunita $x účinky léků $7 D007113
650    _2
$a mladý dospělý $7 D055815
650    _2
$a lymfocyty $x imunologie $x účinky léků $7 D008214
650    _2
$a podskupiny lymfocytů $x imunologie $x účinky léků $7 D016131
650    _2
$a mezibuněčná komunikace $7 D002450
655    _2
$a časopisecké články $7 D016428
700    1_
$a Čermáková, Eva $u Department of Medical Biophysics, Medical Faculty of Charles University, Hradec Králové, 50002, Czech republic
700    1_
$a Krejsek, Jan $u Department of Clinical Immunology and Allergy, Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, 50002, Czech Republic
700    1_
$a Čelakovská, Jarmila $u Department of Dermatology and Venereology, Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, 50002, Czech Republic. Electronic address: celakovskaj@lfhk.cuni.cz
773    0_
$w MED00006034 $t International immunopharmacology $x 1878-1705 $g Roč. 136 (20240530), s. 112327
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38820963 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133822 $b ABA008
999    __
$a ok $b bmc $g 2143249 $s 1225184
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 136 $c - $d 112327 $e 20240530 $i 1878-1705 $m International immunopharmacology $n Int Immunopharmacol $x MED00006034
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...